Related Experiment Video

Updated: May 20, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Angiographic and clinical outcomes of stent postdilatation in ST-elevation myocardial infarction

Sinjini Biswas1, Kean H Soon, Yean L Lim

  • 1Royal Melbourne Hospital, Melbourne, Australia. sinjini@gmail.com

Heart, Lung & Circulation
|July 24, 2012
PubMed

Insights

Stent postdilatation after percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI) does not negatively impact angiographic results or long-term outcomes. This procedure appears safe and effective in STEMI patients, showing no increased risk of major adverse cardiac events.

Area of Science:

  • Cardiovascular Interventions
  • Interventional Cardiology
  • Acute Myocardial Infarction Research

Background:

  • Stent postdilatation is a common practice in percutaneous coronary intervention (PCI) to optimize stent deployment.
  • Its use in ST-elevation myocardial infarction (STEMI) is debated due to concerns about thrombus embolization and no-reflow.
  • This study investigates the safety and efficacy of stent postdilatation in STEMI patients.

Purpose of the Study:

  • To evaluate the immediate angiographic effects of stent postdilatation in STEMI.
  • To assess the long-term clinical outcomes following stent postdilatation in STEMI.
  • To determine if stent postdilatation increases the risk of adverse events in STEMI patients.

Main Methods:

  • Retrospective observational study of 160 STEMI patients undergoing primary PCI.
  • Comparison of patients with and without stent postdilatation.
  • Assessment of final TIMI coronary flow (TMF) and TIMI myocardial perfusion (TMP) scores.
  • Evaluation of major adverse cardiac events (MACE) at 1, 6, and 12 months.

Main Results:

  • No significant differences in final TMF or TMP between postdilatation and no-postdilatation groups.
  • Similar MACE-free survival rates at 12 months (85.1% vs. 86.9%).
  • Patient demographics and procedural characteristics were comparable between groups.

Conclusions:

  • Stent postdilatation in STEMI does not appear to compromise immediate angiographic results.
  • The procedure is associated with similar long-term clinical outcomes and MACE rates compared to no postdilatation.
  • Stent postdilatation can be considered a safe adjunct in STEMI management.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...